Detailed information for compound 254771

Basic information

Technical information
  • TDR Targets ID: 254771
  • Name: (2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydro xy-N-[1-(4-methylpent-3-enyl)piperidin-4-yl]- 2-phenylacetamide
  • MW: 420.536 | Formula: C24H34F2N2O2
  • H donors: 2 H acceptors: 2 LogP: 4.73 Rotable bonds: 8
    Rule of 5 violations (Lipinski): 1
  • SMILES: CC(=CCCN1CCC(CC1)NC(=O)[C@](c1ccccc1)([C@@H]1CCC(C1)(F)F)O)C
  • InChi: 1S/C24H34F2N2O2/c1-18(2)7-6-14-28-15-11-21(12-16-28)27-22(29)24(30,19-8-4-3-5-9-19)20-10-13-23(25,26)17-20/h3-5,7-9,20-21,30H,6,10-17H2,1-2H3,(H,27,29)/t20-,24+/m1/s1
  • InChiKey: KYYKFSMOYWOWFU-YKSBVNFPSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • (2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-N-[1-(4-methylpent-3-enyl)-4-piperidyl]-2-phenyl-acetamide
  • (2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-N-[1-(4-methylpent-3-enyl)-4-piperidinyl]-2-phenylacetamide
  • (2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-N-[1-(4-methylpent-3-enyl)piperidin-4-yl]-2-phenyl-ethanamide

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens cholinergic receptor, muscarinic 2 Starlite/ChEMBL References
Homo sapiens cholinergic receptor, muscarinic 1 Starlite/ChEMBL References
Homo sapiens cholinergic receptor, muscarinic 3 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_133264 All targets in OG5_133264
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_133264 All targets in OG5_133264
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Trypanosoma cruzi GMP reductase 0.0412 0.714 0.5
Leishmania major inosine-5-monophosphate dehydrogenase 0.0412 0.714 0.5
Onchocerca volvulus Putative GMP reductase 0.0171 0 0.5
Trypanosoma cruzi inosine-5'-monophosphate dehydrogenase, putative 0.0412 0.714 0.5
Plasmodium vivax inosine-5'-monophosphate dehydrogenase, putative 0.0388 0.6414 0.5
Trypanosoma cruzi inosine-5'-monophosphate dehydrogenase, putative 0.0412 0.714 0.5
Plasmodium falciparum inosine-5'-monophosphate dehydrogenase 0.0388 0.6414 0.5
Leishmania major guanosine monophosphate reductase 0.0412 0.714 0.5
Loa Loa (eye worm) hypothetical protein 0.0509 1 1
Mycobacterium tuberculosis Probable inosine-5'-monophosphate dehydrogenase GuaB2 (imp dehydrogenase) (inosinic acid dehydrogenase) (inosinate dehydrogenase 0.0412 0.714 1
Schistosoma mansoni inosine-5-monophosphate dehydrogenase 0.0412 0.714 0.5
Mycobacterium leprae Probable inosine-5'-monophosphate dehydrogenase GuaB3 (IMP dehydrogenase 2) (inosinic acid dehydrogenase) (inosinate dehydrogena 0.0216 0.1337 0.0954
Trypanosoma cruzi GMP reductase 0.0412 0.714 0.5
Mycobacterium ulcerans inosine 5-monophosphate dehydrogenase 0.0388 0.6414 0.8869
Wolbachia endosymbiont of Brugia malayi IMP dehydrogenase 0.0412 0.714 0.5
Mycobacterium leprae Probable inosine-5'-monophosphate dehydrogenase GuaB2 (IMP dehydrogenase) (IMPDH) (IMPD) 0.0412 0.714 1
Echinococcus multilocularis inosine 5' monophosphate dehydrogenase 2 0.0412 0.714 1
Trypanosoma brucei GMP reductase 0.0412 0.714 0.5
Echinococcus granulosus inosine 5' monophosphate dehydrogenase 2 0.0412 0.714 1
Loa Loa (eye worm) IMP dehydrogenase 1 0.0412 0.714 0.714
Toxoplasma gondii IMP dehydrogenas 0.0412 0.714 0.5
Trypanosoma brucei inosine-5'-monophosphate dehydrogenase 0.0412 0.714 0.5
Brugia malayi inosine-5'-monophosphate dehydrogenase family protein 0.0412 0.714 1
Trypanosoma cruzi inosine-5'-monophosphate dehydrogenase, putative 0.0412 0.714 0.5
Mycobacterium ulcerans inosine 5'-monophosphate dehydrogenase 0.0412 0.714 1

Activities

Activity type Activity value Assay description Source Reference
Activity (functional) = 4.2 Metacholine provocation test was conducted 4 hr after oral administration of the compound (1 mg/kg) in anesthetized dogs. The bronchodilatory activity is expressed as shifts ChEMBL. 11150173
Ki (binding) = 6.2 nM Inhibition of [3H]-NMS binding to human muscarinic acetylcholine receptor M3 expressed in CHO cells ChEMBL. 11150173
Ki (binding) = 6.2 nM Inhibition of [3H]-NMS binding to human muscarinic acetylcholine receptor M3 expressed in CHO cells ChEMBL. 11150173
Ki (binding) = 22 nM Inhibition of [3H]-NMS binding to human muscarinic acetylcholine receptor M1 expressed in CHO cells ChEMBL. 11150173
Ki (binding) = 22 nM Inhibition of [3H]-NMS binding to human muscarinic acetylcholine receptor M1 expressed in CHO cells ChEMBL. 11150173
Ki (binding) = 2000 nM Inhibition of [3H]-NMS binding to human muscarinic acetylcholine receptor M2 expressed in CHO cells ChEMBL. 11150173
Ki (binding) = 2000 nM Inhibition of [3H]-NMS binding to human muscarinic acetylcholine receptor M2 expressed in CHO cells ChEMBL. 11150173
Metabolic stability (functional) = 68 % In vitro metabolic stability in human hepatic microsomes (1 mg protein/mL), expressed as the percent remaining after 30 min of incubation at 37uM. ChEMBL. 11150173
Metabolic stability (functional) = 70 % In vitro metabolic stability in dog hepatic microsomes (1 mg protein/mL), expressed as the percent remaining after 30 min of incubation at 37uM. ChEMBL. 11150173
Selectivity (binding) = 330 Selectivity ratio between m2 muscarinic and m3 muscarinic receptors ChEMBL. 11150173

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.